The Omnipresence of DYRK1A in Human Diseases
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
The increasing population will challenge healthcare, particularly because the worldwide population has never been older. Therapeutic solutions to age-related disease will be increasingly critical. Kinases are key regulators of human health and represent promising therapeutic targets for novel drug candidates. The dual-specificity tyrosine-regulated kinase (DYRKs) family is of particular interest and, among them, DYRK1A has been implicated ubiquitously in varied human diseases. Herein, we focus on the characteristics of DYRK1A, its regulation and functional role in different human diseases, which leads us to an overview of future research on this protein of promising therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 DYRK family of proteins origins and specificities in humans (based on [10,14,15,16,17,18,19,20]). The percentage of conservation at the protein level between orthologues is indicated above the arrows and between two paralogues is indicated in parentheses within the boxes.](https://figures.cochat.ai/paper-figures/2031cafd490f4ed6b329324cb44c3e7b/the-omnipresence-of-dyrk1a-in-human-diseases-figure-1.jpg)
![Figure 2 Schematic representation of the protein sequences of the 5 human DYRKs (from uniport.org and based on [10,24]). The different protein motifs identified are indicated: NLS, nuclear localization signal; DH, DYRK-homology box; NAPA, N-terminal autophosphorylation accessory region; kinase, kinase domain; PEST, motif rich in proline, glutamic acid, serine, and threonine residues; His, polyhistidine domain; S/T, serine and threonine-enriched domain; and Y, tyrosine residue autophosphorylated by DYRKs within the activation loop. Turquoise lines indicate protein regions affected by alternative splicing events.](https://figures.cochat.ai/paper-figures/489442554f2f4f6e8bc3369a33e3aeaa/the-omnipresence-of-dyrk1a-in-human-diseases-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that overexpression of dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) may influence the initial progression of AD through mechanisms including the hyperphosphorylation of pathologically relevant substrates such as tau, APP, PS1, regulation of axonal transport of APP, and participation in the selective splicing of tau pre-mRNA,500–502”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [502]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698
A brief history of human disease genetics
Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., Kathiresan, S., Kenny, E. E., Lindgren, C. M., MacArthur, D. G., et al. (2020) · Nature · doi:10.1038/s41586-019-1879-7 · Cited by 697 · cited 1×
“Over the past 25 years, technological advances in genomics and analytical approaches have permitted the dissection of the human genome in unprecedented depth, greatly expanding our understanding of many diseases, and facilitating the identification of currently understudied, but potentially druggable, proteins [3,4].”
BackgroundHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection
Wei, J., Alfajaro, M. M., DeWeirdt, P. C., Hanna, R. E., Lu-Culligan, W. J., Cai, W. L., Strine, M. S., Zhang, S.-M., Graziano, V. R., Schmitz, C. O., et al. (2021) · Cell · doi:10.1016/j.cell.2020.10.028 · Cited by 527
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378 · cited 1×
“Over the past 25 years, technological advances in genomics and analytical approaches have permitted the dissection of the human genome in unprecedented depth, greatly expanding our understanding of many diseases, and facilitating the identification of currently understudied, but potentially druggable, proteins [3,4].”
BackgroundDown's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
Baek, K.-H., Zaslavsky, A., Lynch, R. C., Britt, C., Okada, Y., Siarey, R. J., Lensch, M. W., Park, I.-H., Yoon, S. S., Minami, T., et al. (2009) · Nature · doi:10.1038/nature08062 · Cited by 373
Fotaki, V., Dierssen, M., Alcántara, S., Martínez, S., Martí, E., Casas, C., Visa, J., Soriano, E., Estivill, X., & Arbonés, M. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6636-6647.2002 · Cited by 338
Aranda, S., Laguna, A., & Luna, S. D. L. (2011) · The FASEB Journal · doi:10.1096/fj.10-165837 · Cited by 331
da Costa Martins, P. A., Salic, K., Gladka, M. M., Armand, A.-S., Leptidis, S., el Azzouzi, H., Hansen, A., Coenen-de Roo, C. J., Bierhuizen, M. F., van der Nagel, R., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2126 · Cited by 323
Activation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs
Lochhead, P. A., Sibbet, G., Morrice, N., & Cleghon, V. (2005) · Cell · doi:10.1016/j.cell.2005.03.034 · Cited by 323
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly
Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P., & DeCaprio, J. A. (2011) · Genes & Development · doi:10.1101/gad.2034211 · Cited by 302
Taira, N., Nihira, K., Yamaguchi, T., Miki, Y., & Yoshida, K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.007 · Cited by 295
The role of DYRK1A in neurodegenerative diseases
Wegiel, J., Gong, C., & Hwang, Y. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 284
Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281
The Molecular Basis of Leukemia
Gilliland, D. G., Jordan, C. T., & Felix, C. A. (2004) · Hematology · doi:10.1182/asheducation-2004.1.80 · Cited by 273
Metabolomics of type 1 and type 2 diabetes
Arneth, B., Arneth, R., & Shams, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102467 · Cited by 262
Kentrup, H., Becker, W., Heukelbach, J., Wilmes, A., Schürmann, A., Huppertz, C., Kainulainen, H., & Joost, H.-G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3488 · Cited by 259
DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1
Guo, X., Williams, J. G., Schug, T. T., & Li, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102574 · Cited by 240
Activation, regulation, and inhibition of DYRK1A
Becker, W., & Sippl, W. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07956.x · Cited by 227
Ryoo, S., Cho, H., Lee, H., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 227
MNB/DYRK1A as a multiple regulator of neuronal development
Tejedor, F. J., & Hämmerle, B. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07954.x · Cited by 214
The Risks of miRNA Therapeutics: In a Drug Target Perspective
Zhang, S., Cheng, Z., Wang, Y., & Han, T. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s288859 · Cited by 211
Inhibition of DYRK1A Stimulates Human β-Cell Proliferation
Dirice, E., Walpita, D., Vetere, A., Meier, B. C., Kahraman, S., Hu, J., Dančík, V., Burns, S. M., Gilbert, T. J., Olson, D. E., et al. (2016) · Diabetes · doi:10.2337/db15-1127 · Cited by 209
Himpel, S., PANZER, P., EIRMBTER, K., Czajkowska, H., Sayed, M., Packman, L. C., Blundell, T. L., Kentrup, H., Grötzinger, J., Joost, H., et al. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590497 · Cited by 209
Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID
van Bon, B. W. M., Coe, B. P., Bernier, R., Green, C., Gerdts, J., Witherspoon, K., Kleefstra, T., Willemsen, M. H., Kumar, R., Bosco, P., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.5 · Cited by 204
Soppa, U., Schumacher, J., Florencio Ortiz, V., Pasqualon, T., Tejedor, F., & Becker, W. (2014) · Cell Cycle · doi:10.4161/cc.29104 · Cited by 189
Guimera, J., Casas, C., Estivill, X., & Pritchard, M. (1999) · Genomics · doi:10.1006/geno.1999.5775 · Cited by 186 · cited 2×
“From kidneys to bone marrow, DYRK1A expression is ubiquitously observed in all human tissues from early embryonic development to adulthood [25,26].”
BackgroundFrontotemporal dementia: latest evidence and clinical implications
Young, J. J., Lavakumar, M., Tampi, D., Balachandran, S., & Tampi, R. R. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317739818 · Cited by 186
Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181
Malinge, S., Bliss-Moreau, M., Kirsammer, G., Diebold, L., Chlon, T., Gurbuxani, S., & Crispino, J. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60455 · Cited by 179
Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y.-W., Iqbal, K., Grundke-Iqbal, I., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802645200 · Cited by 178
Ferrer, I., Barrachina, M., Puig, B., Martínez de Lagrán, M., Martí, E., Avila, J., & Dierssen, M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.020 · Cited by 178
Yang, E. J., Ahn, Y. S., & Chung, K. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104091200 · Cited by 172
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 172
DYRK1A and cognition: A lifelong relationship
Arbones, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M., & Delabar, J. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.010 · Cited by 165
DYRK1A: A master regulatory protein controlling brain growth
Guedj, F., Pereira, P. L., Najas, S., Barallobre, M.-J., Chabert, C., Souchet, B., Sebrie, C., Verney, C., Herault, Y., Arbones, M., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.007 · Cited by 158
Chromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase
Vona, C. D., Bezdan, D., Islam, A. B. M. M. K., Salichs, E., López-Bigas, N., Ossowski, S., & de la Luna, S. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.026 · Cited by 157
The Protein Kinase DYRK1A Regulates Caspase-9-Mediated Apoptosis during Retina Development
Laguna, A., Aranda, S., Barallobre, M. J., Barhoum, R., Fernández, E., Fotaki, V., Delabar, J. M., de la Luna, S., de la Villa, P., & Arbonés, M. L. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.10.014 · Cited by 157
How far will global population rise? Researchers can't agree
Adam, D. (2021) · Nature · doi:10.1038/d41586-021-02522-6 · Cited by 146
Smith, B., Medda, F., Gokhale, V., Dunckley, T., & Hulme, C. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300094k · Cited by 144
Self-citationInhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
Pozo, N., Zahonero, C., Fernández, P., Liñares, J. M., Ayuso, A., Hagiwara, M., Pérez, A., Ricoy, J. R., Hernández-Laín, A., Sepúlveda, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63623 · Cited by 140
Lepagnol-Bestel, A.-M., Zvara, A., Maussion, G., Quignon, F., Ngimbous, B., Ramoz, N., Imbeaud, S., Loe-Mie, Y., Benihoud, K., Agier, N., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp047 · Cited by 137
Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system
Martı́, E., Altafaj, X., Dierssen, M., de la Luna, S., Fotaki, V., Alvarez, M., Pérez-Riba, M., Ferrer, I., & Estivill, X. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04069-6 · Cited by 136
Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells
Park, J., Oh, Y., Yoo, L., Jung, M.-S., Song, W.-J., Lee, S.-H., Seo, H., & Chung, K. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147520 · Cited by 134
Dyrk1 inhibition improves Alzheimer's disease‐like pathology
Branca, C., Shaw, D. M., Belfiore, R., Gokhale, V., Shaw, A. Y., Foley, C., Smith, B., Hulme, C., Dunckley, T., Meechoovet, B., et al. (2017) · Aging Cell · doi:10.1111/acel.12648 · Cited by 129
Self-citationAn ID2-dependent mechanism for VHL inactivation in cancer
Lee, S. B., Frattini, V., Bansal, M., Castano, A. M., Sherman, D., Hutchinson, K., Bruce, J. N., Califano, A., Liu, G., Cardozo, T., et al. (2016) · Nature · doi:10.1038/nature16475 · Cited by 128
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Ackeifi, C., Wang, P., Karakose, E., Manning Fox, J. E., González, B. J., Liu, H., Wilson, J., Swartz, E., Berrouet, C., Li, Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw9996 · Cited by 125
Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation
Kim, E. J., Sung, J. Y., Lee, H. J., Rhim, H., Hasegawa, M., Iwatsubo, T., Min, D. S., Kim, J., Paik, S. R., & Chung, K. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606147200 · Cited by 113
Lindberg, M. F., & Meijer, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116047 · Cited by 112
Structural mechanisms of DREAM complex assembly and regulation
Guiley, K. Z., Liban, T. J., Felthousen, J. G., Ramanan, P., Litovchick, L., & Rubin, S. M. (2015) · Genes & Development · doi:10.1101/gad.257568.114 · Cited by 111
Down Syndrome and Malignancies: A Unique Clinical Relationship
Xavier, A. C., Ge, Y., & Taub, J. W. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080132 · Cited by 109
Ryu, Y. S., Park, S. Y., Jung, M., Yoon, S., Kwen, M., Lee, S., Choi, S., Radnaabazar, C., Kim, M., Kim, H., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06769.x · Cited by 108
DYRK1A inhibitors for disease therapy: Current status and perspectives
Liu, T., Wang, Y., Wang, J., Ren, C., Chen, H., & Zhang, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114062 · Cited by 105
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A
Qian, W., Liang, H., Shi, J., Jin, N., Grundke-Iqbal, I., Iqbal, K., Gong, C.-X., & Liu, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr195 · Cited by 101
Sitz, J. H., Baumgärtel, K., Hämmerle, B., Papadopoulos, C., Hekerman, P., Tejedor, F. J., Becker, W. B., & Lutz, B. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.034 · Cited by 100
García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis
Laham, A. J., Saber-Ayad, M. M., & El‐Awady, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03626-4 · Cited by 99
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Luna, J., Boni, J., Cuatrecasas, M., Ros, X. B., Núñez-Manchón, E., Gironella, M., Vaquero, E. C., Arbonés, M. L., de la Luna, S., & Fillat, C. (2018) · Gut · doi:10.1136/gutjnl-2018-316128 · Cited by 97
Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C.-X., Iqbal, K., Grundke-Iqbal, I., & Liu, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355412 · Cited by 93
Najas, S., Arranz, J., Lochhead, P. A., Ashford, A. L., Oxley, D., Delabar, J. M., Cook, S. J., Barallobre, M. J., & Arbonés, M. L. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.01.010 · Cited by 92
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Demuro, S., Martino, R. M. C. D., Ortega, J. A., & Cavalli, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169098 · Cited by 92
Dyrk1A Inhibition as Potential Treatment for Alzheimer’S Disease
Stotani, S., Giordanetto, F., & Medda, F. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0013 · Cited by 90
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Bhansali, R. S., Rammohan, M., Lee, P., Laurent, A. P., Wen, Q., Suraneni, P., Yip, B. H., Tsai, Y.-C., Jenni, S., Bornhauser, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135937 · Cited by 90
Regulation of RCAN1 Protein Activity by Dyrk1A Protein-mediated Phosphorylation
Jung, M.-S., Park, J.-H., Ryu, Y. S., Choi, S.-H., Yoon, S.-H., Kwen, M.-Y., Oh, J. Y., Song, W.-J., & Chung, S.-H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.253971 · Cited by 88
Kelly, P. A., & Rahmani, Z. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1085 · Cited by 86
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
Féki, A., & Hibaoui, Y. (2018) · Brain Sciences · doi:10.3390/brainsci8100187 · Cited by 85
Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A
Fernandez-Martinez, J., Vela, E. M., Tora-Ponsioen, M., Ocaña, O. H., Nieto, M. A., & Galceran, J. (2009) · Journal of Cell Science · doi:10.1242/jcs.044354 · Cited by 84
A subcellular map of the human kinome
Zhang, H., Cao, X., Tang, M., Zhong, G., Si, Y., Li, H., Zhu, F., Liao, Q., Li, L., Zhao, J., et al. (2021) · eLife · doi:10.7554/elife.64943 · Cited by 83
The Kinase Mirk/Dyrk1B Mediates Cell Survival in Pancreatic Ductal Adenocarcinoma
Deng, X., Ewton, D. Z., Li, S. C., Naqvi, A. H., Mercer, S. E., LANDAS, S. K., & Friedman, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3089 · Cited by 82
Glenewinkel, F., Cohen, M. J., King, C. R., Kaspar, S., Bamberg‐Lemper, S., Mymryk, J. S., & Becker, W. B. (2016) · Scientific Reports · doi:10.1038/srep28241 · Cited by 77
Nuclear trafficking of pro-apoptotic kinases in response to DNA damage
Yoshida, K. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.05.003 · Cited by 75
Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling
Hille, S. S., Dierck, F., Kühl, C., Sosna, J., Adam‐Klages, S., Adam, D., Lüllmann‐Rauch, R., Frey, N., & Kühn, C. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw074 · Cited by 75
Nguyen, T. L., Fruit, C., Hérault, Y., Meijer, L., & Besson, T. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1360285 · Cited by 74
Song, W.-J., Song, E.-A. C., Jung, M.-S., Choi, S.-H., Baik, H.-H., Jin, B. K., Kim, J. H., & Chung, S.-H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594952 · Cited by 72
Neumann, F., Gourdain, S., Albac, C., Dekker, A. D., Bui, L. C., Dairou, J., Schmitz-Afonso, I., Hue, N., Rodrigues-Lima, F., Delabar, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20984-z · Cited by 71
Li, Y., Xie, X., Jie, Z., Zhu, L., Yang, J., Ko, C., Gao, T., Jain, A., Jung, S. Y., Baran, N., et al. (2021) · Blood · doi:10.1182/blood.2021011247 · Cited by 71
Murakami, N., Xie, W., Lu, R. C., Chen-Hwang, M.-C., Wieraszko, A., & Hwang, Y. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513497200 · Cited by 70
Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B., Tjitro, A., Anderson, S. D., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 69
Rammohan, M., Harris, E., Bhansali, R. S., Zhao, E., Li, L. S., & Crispino, J. D. (2022) · Oncogene · doi:10.1038/s41388-022-02245-6 · Cited by 68
Dyrk1A Potentiates Steroid Hormone-Induced Transcription via the Chromatin Remodeling Factor Arip4
Sitz, J. H., Tigges, M., Baumgärtel, K., Khaspekov, L. G., & Lutz, B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5821-5834.2004 · Cited by 65
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair
Guard, S. E., Poss, Z. C., Ebmeier, C. C., Pagratis, M., Simpson, H., Taatjes, D. J., & Old, W. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42990-5 · Cited by 63
Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A
Ding, S., Shi, J., Qian, W., Iqbal, K., Grundke-Iqbal, I., Gong, C.-X., & Liu, F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.021 · Cited by 61
Jang, S. M., Azébi, S., Soubigou, G., & Muchardt, C. (2014) · EMBO Reports · doi:10.15252/embr.201338356 · Cited by 59
DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures
Raveau, M., Shimohata, A., Amano, K., Miyamoto, H., & Yamakawa, K. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.003 · Cited by 58
Li, Y.-L., Ding, K., Hu, X., Wu, L., Zhou, D., Rao, M., Lin, N., & Zhang, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14609 · Cited by 58
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression
von Groote-Bidlingmaier, F., Schmoll, D., Orth, H., Joost, H., Becker, W. B., & Barthel, A. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02914-5 · Cited by 55
Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome
Laguna, A., Barallobre, M.-J., Marchena, M.-Á., Mateus, C., Ramírez, E., Martínez-Cue, C., Delabar, J. M., Castelo-Branco, M., de la Villa, P., & Arbonés, M. L. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt125 · Cited by 55
R. Menon, V., Ananthapadmanabhan, V., Swanson, S., Saini, S., Sesay, F., Yakovlev, V., Florens, L., DeCaprio, J. A., P. Washburn, M., Dozmorov, M., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1577525 · Cited by 55
Sacher, F., Möller, C., Bone, W., Gottwald, U., & Fritsch, M. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.12.041 · Cited by 52
Chiu, C.-C., Yeh, T.-H., Chen, R.-S., Chen, H.-C., Huang, Y.-Z., Weng, Y.-H., Cheng, Y.-C., Liu, Y.-C., Cheng, A.-J., Lu, Y.-C., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00399 · Cited by 51
Barallobre, M. J., Perier, C., Bové, J., Laguna, A., Delabar, J. M., Vila, M., & Arbonés, M. L. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.253 · Cited by 50
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells
Recasens, A., Humphrey, S. J., Ellis, M., Hoque, M., Abbassi, R. H., Chen, B., Longworth, M., Needham, E. J., James, D. E., Johns, T. G., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00456-6 · Cited by 50
Papadopoulos, C., Arato, K., Lilienthal, E., Zerweck, J., Schutkowski, M., Chatain, N., Müller-Newen, G., Becker, W., & de la Luna, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157909 · Cited by 49
Arranz, J., Balducci, E., Arató, K., Sánchez‐Elexpuru, G., Najas, S., Parras, A., Rebollo, E., Pijuan, I., Erb, I., Verde, G., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.022 · Cited by 48
Grau, C., Arató, K., Fernández-Fernández, J. M., Valderrama, A., Sindreu, C., Fillat, C., Ferrer, I., de la Luna, S., & Altafaj, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00331 · Cited by 47
Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin
Dong, C., West, K. L., Tan, X. Y., Li, J., Ishibashi, T., Yu, C., Sy, S. M.-H., Leung, J. W. C., & Huen, M. S. Y. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002193117 · Cited by 47
Dyrk1A Binds to Multiple Endocytic Proteins Required for Formation of Clathrin-Coated Vesicles
Murakami, N., Bolton, D., & Hwang, Y.-W. (2009) · Biochemistry · doi:10.1021/bi9010557 · Cited by 45
Kang, J. E., Choi, S. A., Park, J. B., & Chung, K. C. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20534 · Cited by 45
Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice
Velázquez, R., Meechoovet, B., Ow, A., Foley, C., Shaw, A. Y., Smith, B. E., Oddo, S., Hulme, C., & Dunckley, T. L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01684-9 · Cited by 44
Self-citationIntegrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder
Courraud, J., Chater‐Diehl, E., Durand, B., Vincent, M., Moreno, M. D. M. M., Boujelbene, I., Drouot, N., Genschik, L., Schaefer, É., Nizon, M., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01263-1 · Cited by 44
Brault, V., Nguyen, T. L., Flores-Gutiérrez, J., Iacono, G., Birling, M.-C., Lalanne, V., Meziane, H., Manousopoulou, A., Pavlovic, G., Lindner, L., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009777 · Cited by 44
Frontotemporal Dementia, Pick Disease, and Corticobasal Degeneration: One Entity or 3? 1
Kertesz, A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550230090024 · Cited by 40
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
Weber, C., Sipos, M., Paczal, A., Balint, B., Kun, V., Foloppe, N., Dokurno, P., Massey, A. J., Walmsley, L., Hubbard, R. E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00023 · Cited by 39
Adayev, T., Chen‐Hwang, M., Murakami, N., Lee, E., Bolton, D. C., & Hwang, Y. (2007) · Biochemistry · doi:10.1021/bi700251n · Cited by 38
Liang, Y., Chang, H., Wang, C.-Y., & Yu, W. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.04.003 · Cited by 38
Ehe, B. K., Lamson, D. R., Tarpley, M., Onyenwoke, R. U., Graves, L. M., & Williams, K. P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.107 · Cited by 38
Walter, C., Marada, A., Suhm, T., Ernsberger, R., Muders, V., Küçükköse, C., Sánchez‐Martín, P., Hu, Z., Aich, A., Loroch, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24426-9 · Cited by 38
DYRK1A regulates Hap1–Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome
Xiang, J., Yang, S., Xin, N., Gaertig, M. A., Reeves, R. H., Li, S., & Li, X.-J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614893114 · Cited by 37
Disrupting the DREAM complex enables proliferation of adult human pancreatic β cells
Wang, P., Karaköse, E., Argmann, C., Wang, H., Balev, M., Brody, R., Rivas, H. G., Liu, X., Wood, O., Liu, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157086 · Cited by 36
Dyrk1A phosphorylates parkin at Ser‐131 and negatively regulates its ubiquitin E3 ligase activity
Im, E., & Chung, K. C. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13164 · Cited by 34
AlNajjar, Y. T., Gabr, M. T., ElHady, A. K., Salah, M., Wilms, G., Abadi, A., Becker, W. B., Abdel‐Halim, M., & Engel, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113911 · Cited by 34
Kawakubo, T., Mori, R., Shirotani, K., Iwata, N., & Asai, M. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00825 · Cited by 32
Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells
Bellmaine, S. F., Ovchinnikov, D. A., Manallack, D. T., Cuddy, C., Elefanty, A. G., Stanley, E. G., Wolvetang, E. J., Williams, S. J., & Pera, M. F. (2017) · eLife · doi:10.7554/elife.24502 · Cited by 32
DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
Barzowska, A., Pucelik, B., Pustelny, K., Matsuda, A., Martyniak, A., Stępniewski, J., Maksymiuk, A., Dawidowski, M., Rothweiler, U., Dulak, J., et al. (2021) · Cells · doi:10.3390/cells10092263 · Cited by 30
DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner
Booiman, T., Loukachov, V. V., van Dort, K. A., Wout, A. B. V. ’., & Kootstra, N. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144229 · Cited by 28
Shahroz, M. M., Sharma, H. K., Altamimi, A. S. A., Alamri, M. A., Ali, A., Ali, A., Alqahtani, S. M., Altharawi, A., Alabbas, A. B., Alossaimi, M. A., et al. (2022) · Molecules · doi:10.3390/molecules27041159 · Cited by 28
Interplay Between CMGC Kinases Targeting SR Proteins and Viral Replication: Splicing and Beyond
Pastor, F., Shkreta, L., Chabot, B., Durantel, D., & Salvetti, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.658721 · Cited by 27
DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies
Belgardt, B., & Lammert, E. (2016) · Diabetes · doi:10.2337/dbi16-0013 · Cited by 25
Lee, Y. H., Im, E., Hyun, M., Park, J., & Chung, K. C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015574 · Cited by 25
Bescond, M., & Rahmani, Z. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.12.006 · Cited by 24
Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
Pucelik, B., Barzowska, A., Dąbrowski, J. M., & Czarna, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169083 · Cited by 23
CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer
Lan, B., Zeng, S., Zhang, S., Ren, X., Xing, Y., Kutschick, I., Pfeffer, S., Frey, B., Britzen‐Laurent, N., Grützmann, R., et al. (2022) · Cancers · doi:10.3390/cancers14020326 · Cited by 22
Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21
Mumford, P., Tosh, J., Anderle, S., Gkanatsiou Wikberg, E., Lau, G., Noy, S., Cleverley, K., Saito, T., Saido, T. C., Yu, E., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0521-22.2022 · Cited by 22
Kisaka, J. K., Ratner, L., & Kyei, G. B. (2019) · Journal of Virology · doi:10.1128/jvi.01583-19 · Cited by 21
DYRK1A Regulates the Bidirectional Axonal Transport of APP in Human-Derived Neurons
Fernandez Bessone, I., Navarro, J., Martinez, E., Karmirian, K., Holubiec, M., Alloatti, M., Goto-Silva, L., Arnaiz Yepez, C., Martins-de-Souza, D., Minardi Nascimento, J., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.2551-21.2022 · Cited by 21
Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00346 · Cited by 17
RCAN1 in the inverse association between Alzheimer’s disease and cancer
Fu, Q., & Wu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23094 · Cited by 16
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches
Yoon, H. R., Balupuri, A., Choi, K.-E., & Kang, N. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186826 · Cited by 16
Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats
Raaf, L., Noll, C., Cherifi, M., Benazzoug, Y., Delabar, J. M., & Janel, N. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.10.043 · Cited by 14
Disease Modeling of Rare Neurological Disorders in Zebrafish
Son, M., Kim, D. Y., & Kim, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073946 · Cited by 12
Brault, V., Nguyen, T. L., Gutiérrez, J. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.01.442242 · Cited by 8
Small-molecule discovery in the pancreatic beta cell
Wagner, B. K. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102150 · Cited by 7
Two drugs converged in a pancreatic β cell
Scavuzzo, M. A., & Borowiak, M. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba7359 · Cited by 6
Enjalbert, A., & Pechon-Vallée, C. L. (2003) · Elsevier eBooks · doi:10.1016/b0-12-341103-3/00258-8 · Cited by 3
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“…relevant substrates such as tau, APP, PS1, regulation of axonal transport of APP, and participation in the selective splicing of tau pre-mRNA, 500 – 502 the compound dp-FINDY ( 37 ) effectively targets the spatial dynamic changes in the ATP-binding site between the DYRK1A folding intermediate and…”
BackgroundComparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Lindberg, M. F., Deau, E., Arfwedson, J., George, N. S., George, P. G., Alfonso, P., Corrionero, A., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02068 · Cited by 54
Lindberg, M. F., Deau, E., Miege, F., Greverie, M., Roche, D., George, N. S., George, P. G., Merlet, L., Gavard, J., Brugman, S. J. T., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01888 · Cited by 52
Deau, E., Lindberg, M. F., Miege, F., Roche, D., George, N. S., George, P. G., Krämer, A., Knapp, S., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00884 · Cited by 41
Meijer, L., Chrétien, E., & Ravel, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240078 · Cited by 33
Metadata
- Authors
- Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T.
- Affiliations
- Arizona State University (US)
- University of Arizona (US)
- Corresponding author
- Deboever, Estelle
- Dunckley, Travis
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-19
- Volume
- 23
- Issue
- 16
- Pages
- 9355
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9408930
- OpenAlex
- W4293678299
- Cited by
- 77
- References
- 143
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 20 · 2023: 11
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Edson Family Foundation (38526, 1R01NS109422-01A1)
- NIA grant (38526, 1R01NS109422-01A1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- DYRK1A, kinases, age-related diseases, therapeutic target, kinase regulation, human disease, drug candidates
- MeSH terms
- Dyrk Kinases, Disease, Humans, Protein-Tyrosine Kinases, Protein Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.